Evidence map›Paper›PMID 26822946›Full record

ArticleCancer imaging : the official publication of the International Cancer Imaging Society2016

Intravoxel incoherent motion MRI as a biomarker of sorafenib treatment for advanced hepatocellular carcinoma: a pilot study.

Natsuhiko Shirota, Kazuhiro Saito, Katsutoshi Sugimoto, Kenichi Takara, Fuminori Moriyasu, Koichi Tokuuye

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Bi-exponential fitting excludingQuantitative imaging in medicine and surgery · 2022
    Article
  8. Article
  9. Review
  10. Review
  11. Perfusion-driven Intravoxel Incoherent Motion (IVIM) MRI in Oncology: Applications, Challenges, and Future Trends.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2021
    Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Natsuhiko ShirotaDepartment of Radiology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan. rad_shirota@yahoo.co.jp.
Kazuhiro SaitoDepartment of Radiology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan. saito-k@tokyo-med.ac.jp.
Katsutoshi SugimotoDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan. sugimoto@tokyo-med.ac.jp.
Kenichi TakaraDepartment of Radiology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan. takarayrc@yahoo.co.jp.
Fuminori MoriyasuDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan. moriyasu@tokyo-med.ac.jp.
Koichi TokuuyeDepartment of Radiology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan. ktokuue@tokyo-med.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo evaluate the association between the therapeutic outcomes of sorafenib for advanced hepatocellular carcinoma (HCC) and the parameters of intravoxel incoherent motion (IVIM).

methodsNine patients were evaluated prospectively. All patients were Child-Pugh score A. The mean dimension of the lesion was 32 mm (range: 15-74 mm). MR images were obtained using a 1.5-Tesla superconductive MRI system. Diffusion-weighted imaging was performed under breath-holding using b-values of 0, 50, 100, 150, 200, 400, and 800 s/mm(2). The following IVIM parameters were calculated: apparent diffusion coefficient, true diffusion coefficient (DC), pseudo-diffusion coefficient, and perfusion fraction. MRI was performed before treatment and at 1, 2, and 4 weeks after beginning treatment. Tumor response at 4 weeks was assessed by CT or MRI using modified RECIST. IVIM parameters of the treatment responders and non-responders were compared.

resultsThe DC of responders at baseline was significantly higher than that of the non-responders. The sensitivity and specificity, when a DC of 0.8 (10(-3) mm(2)/s) or higher was considered to be a responder, were 100 % and 67 %, respectively. No significant differences were found in the other parameters between the responders and the non-responders. All IVIM parameters of the responders and non-responders did not change significantly after treatment.

conclusionThe DC before treatment may be a useful parameter for predicting the therapeutic outcome of sorafenib for advanced HCC.

Indexed as

AgedAlgorithmsAntineoplastic AgentsBiomarkersCarcinoma, HepatocellularContrast MediaDiffusion Magnetic Resonance ImagingDisease ProgressionFemaleFollow-Up StudiesHumansImage Processing, Computer-AssistedLiver NeoplasmsMaleMiddle AgedMultidetector Computed TomographyAntineoplastic AgentsBiomarkersContrast MediaNiacinamidePhenylurea CompoundsProtein Kinase Inhibitorsraf KinasesSorafenib

Identifiers

PMID26822946
PMCPMC4731920

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.